Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

By sjmartinez • April 9, 2025

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman JT, Ramgopal M. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Res Ther. 2025 Apr 7;22(1):45. doi: 10.1186/s12981-025-00732-w. PMID: 40197415; PMCID: PMC11978100.

Tags: antiretroviral therapy, Bictegravir, body mass index, dolutegravir, glucose, Harbor UCLA, HIV-1, Infectious Diseases, Publications, Tenofovir alafenamide

Opportunistic Chest CT Paraspinal Muscle Biomarkers to Predict Longitudinal Thoracic Vertebral Bone Mineral Density Loss: Results from MESA

Hathaway QA, Ghotbi E, Pan T, Momtazmanesh S, Klein JG, Allison M, Barbosa EJM Jr, Barr RG, Bluemke DA, Lima JAC, Post W, Tison GH,[...]

Building Families-Implementing Balanced Sexual and Reproductive Health: A Joint IFFS and ISA Scientific Statement

Liu PY, Mocanu E, Giudice L, Horton M, Nigdelis MP, Perheentupa A, Sansone A, Corona G, Gianaroli L, Goulis DG. Building Families-Implementing Balanced Sexual and[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]